

# Satoshi Sakai

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11978464/publications.pdf>

Version: 2024-02-01

65  
papers

3,106  
citations

218381

26  
h-index

155451

55  
g-index

66  
all docs

66  
docs citations

66  
times ranked

2809  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Potential of Gold Nanoparticles for Noninvasive Imaging and Therapy for Vascular Inflammation. <i>Molecular Imaging and Biology</i> , 2022, 24, 692-699.   | 1.3 | 3         |
| 2  | Generation of Transgenic Mice that Conditionally Overexpress Tenascin-C. <i>Frontiers in Immunology</i> , 2021, 12, 620541.  | 2.2 | 7         |
| 3  | Long-term treatment of pulmonary arterial hypertension with macitentan in Japanese patients. <i>Current Medical Research and Opinion</i> , 2020, 36, 921-928.  | 0.9 | 4         |
| 4  | Endothelin and the heart in health and diseases. <i>Peptides</i> , 2019, 111, 77-88.   | 1.2 | 39        |
| 5  | Tenascin-C accelerates adverse ventricular remodelling after myocardial infarction by modulating macrophage polarization. <i>Cardiovascular Research</i> , 2019, 115, 614-624.   | 1.8 | 50        |
| 6  | MicroRNA-205-5p suppresses the invasiveness of oral squamous cell carcinoma by inhibiting TIMP2 expression. <i>International Journal of Oncology</i> , 2018, 52, 841-850.  | 1.4 | 23        |
| 7  | Exercise habituation is effective for improvement of periodontal disease status: a prospective intervention study. <i>Therapeutics and Clinical Risk Management</i> , 2018, Volume 14, 565-574.  | 0.9 | 19        |
| 8  | Abstract 533: Gold Nanoparticles Allow CT Imaging of Experimental Atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, .   | 1.1 | 0         |
| 9  | The effectiveness of upfront pulmonary vasodilators combination therapy in addition to corticosteroids for pulmonary arterial hypertension associated with systemic lupus erythematosus: two successful cases utilising both corticosteroids and an upfront combination of vasodilators. <i>Modern Rheumatology Case Reports</i> , 2017, 1, 73-78. | 0.3 | 1         |
| 10 | Efficacy and Safety of an Orally Administered Selective Prostacyclin Receptor Agonist, Selexipag, in Japanese Patients With Pulmonary Arterial Hypertension. <i>Circulation Journal</i> , 2017, 81, 1360-1367.   | 0.7 | 19        |
| 11 | MicroRNA-155 is associated with oral squamous cell carcinoma metastasis and poor prognosis. <i>Journal of Oral Pathology and Medicine</i> , 2016, 45, 248-255.   | 1.4 | 69        |
| 12 | Antagonists to endothelin receptor type B promote apoptosis in human pulmonary arterial smooth muscle cells. <i>Life Sciences</i> , 2016, 159, 116-120.  | 2.0 | 7         |
| 13 | Bosentan reverses the hypoxia-induced downregulation of the bone morphogenetic protein signaling in pulmonary artery smooth muscle cells. <i>Life Sciences</i> , 2016, 159, 111-115.   | 2.0 | 8         |
| 14 | p62 modulates the intrinsic signaling of UVB-induced apoptosis. <i>Journal of Dermatological Science</i> , 2016, 83, 226-233.  | 1.0 | 8         |
| 15 | Endothelin-Bone morphogenetic protein type 2 receptor interaction induces pulmonary artery smooth muscle cell hyperplasia in pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 468-478.  | 0.3 | 29        |
| 16 | Tenascin-C Aggravates Autoimmune Myocarditis via Dendritic Cell Activation and Th17 Cell Differentiation. <i>Journal of the American Heart Association</i> , 2014, 3, e001052.   | 1.6 | 64        |
| 17 | Endothelin receptor antagonist exacerbates autoimmune myocarditis in mice. <i>Life Sciences</i> , 2014, 118, 288-296.  | 2.0 | 10        |
| 18 | Calcitonin gene-related peptide protects the myocardium from ischemia induced by endothelin-1: Intravital microscopic observation and 31P-MR spectroscopic studies. <i>Life Sciences</i> , 2014, 118, 248-254.   | 2.0 | 25        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Mechanisms explaining the late "catch-up" phenomenon after sirolimus-eluting stent implantation. <i>International Journal of Cardiology</i> , 2014, 177, 44-45.  | 0.8 | 2         |
| 20 | Effects of selective endothelin (ET)-A receptor antagonist versus dual ET-A/B receptor antagonist on hearts of streptozotocin-treated diabetic rats. <i>Life Sciences</i> , 2014, 111, 6-11.   | 2.0 | 10        |
| 21 | Fish oil constituent eicosapentaenoic acid inhibits endothelin-induced cardiomyocyte hypertrophy via PPAR- $\alpha$ . <i>Life Sciences</i> , 2014, 118, 173-178.   | 2.0 | 10        |
| 22 | Involvement of peptidyl-prolyl isomerase Pin1 in the inhibitory effect of fluvastatin on endothelin-1-induced cardiomyocyte hypertrophy. <i>Life Sciences</i> , 2014, 102, 98-104.   | 2.0 | 13        |
| 23 | Clinical value of plasma pentraxin 3 levels for predicting cardiac troponin elevation after percutaneous coronary intervention. <i>Life Sciences</i> , 2014, 95, 40-44.  | 2.0 | 6         |
| 24 | Abstract 13522: Vascular Healing in Drug-Eluting Stents: Differential Response of Limus-Eluting Stents in a Preclinical Model of Stent Implantation. <i>Circulation</i> , 2014, 130, .   | 1.6 | 0         |
| 25 | Abstract 13566: Pitavastatin Regulates mTOR Complex 1 Signaling Through Inhibition of Rheb in T Cells. <i>Circulation</i> , 2014, 130, .   | 1.6 | 1         |
| 26 | Negative expression of N-acetylglucosaminyltransferase V in oral squamous cell carcinoma correlates with poor prognosis. <i>SpringerPlus</i> , 2013, 2, 657.   | 1.2 | 8         |
| 27 | Endothelin-1-induced cardiomyocyte hypertrophy is partly regulated by transcription factor II-F interacting C-terminal domain phosphatase of RNA polymerase II. <i>Life Sciences</i> , 2012, 91, 572-577.  | 2.0 | 6         |
| 28 | The benefit of medium-chain triglyceride therapy on the cardiac function of SHR is associated with a reversal of metabolic and signaling alterations. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2008, 295, H136-H144.   | 1.5 | 21        |
| 29 | Endothelin-1-induced Cardiac Hypertrophy Is Inhibited by Activation of Peroxisome Proliferator-activated Receptor- $\alpha$ Partly Via Blockade of c-Jun NH2-Terminal Kinase Pathway. <i>Circulation</i> , 2004, 109, 904-910.   | 1.6 | 112       |
| 30 | Activation of Peroxisome Proliferator-activated Receptor- $\alpha$ Decreases Endothelin-1-induced p38 Mitogen-activated Protein Kinase Activation in Cardiomyocytes. <i>Journal of Cardiovascular Pharmacology</i> , 2004, 44, S358-S361.  | 0.8 | 29        |
| 31 | Chronic Administration of an Endothelin-A Receptor Antagonist Improves Exercise Capacity in Rats with Myocardial Infarction-induced Congestive Heart Failure. <i>Journal of Cardiovascular Pharmacology</i> , 2004, 44, S64-S67.   | 0.8 | 16        |
| 32 | Activation of cardiac Cdk9 represses PGC-1 and confers a predisposition to heart failure. <i>EMBO Journal</i> , 2004, 23, 3559-3569.   | 3.5 | 145       |
| 33 | Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-kappa-b pathway. <i>Journal of the American College of Cardiology</i> , 2004, 43, 1481-1488. | 1.2 | 158       |
| 34 | The endothelin receptor antagonist ameliorates the hypertensive phenotypes of transgenic hypertensive mice with renin-angiotensin genes and discloses roles of organ specific activation of endothelin system in transgenic mice. <i>Life Sciences</i> , 2004, 74, 1105-1118.  | 2.0 | 7         |
| 35 | YM598, an Orally Active ETA Receptor Antagonist, Ameliorates the Progression of Cardiopulmonary Changes and Both-side Heart Failure in Rats with Cor Pulmonale and Myocardial Infarction. <i>Journal of Cardiovascular Pharmacology</i> , 2004, 44, S354-S357.   | 0.8 | 7         |
| 36 | Cardiac Hypertrophy by Hypertension and Exercise Training Exhibits Different Gene Expression of Enzymes in Energy Metabolism. <i>Hypertension Research</i> , 2003, 26, 829-837.  | 1.5 | 66        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | Peroxisome proliferator-activated receptor- $\beta$ activators inhibit endothelin-1-related cardiac hypertrophy in rats. <i>Clinical Science</i> , 2002, 103, 16S-20S.  | 1.8 | 55        |
| 38 | Stimulation of peroxisome-proliferator-activated receptor $\beta$ (PPAR $\beta$ ) attenuates cardiac fibrosis and endothelin-1 production in pressure-overloaded rat hearts. <i>Clinical Science</i> , 2002, 103, 284S-288S.  | 1.8 | 101       |
| 39 | A combination of oral endothelin-receptor antagonist and oral prostacyclinanalogue is superior to each drug alone in ameliorating pulmonary hypertension in rats. <i>Journal of the American College of Cardiology</i> , 2002, 40, 175-181.                         | 1.2 | 27        |
| 40 | Aging-induced decrease in the PPAR- $\beta$ level in hearts is improved by exercise training. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2002, 283, H1750-H1760.  | 1.5 | 159       |
| 41 | Physiological and pathological cardiac hypertrophy induce different molecular phenotypes in the rat. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2001, 281, R2029-R2036.  | 0.9 | 111       |
| 42 | Endothelin-A-Receptor Antagonist and Oral Prostacyclin Analog are Comparably Effective in Ameliorating Pulmonary Hypertension and Right Ventricular Hypertrophy in Rats. <i>Journal of Cardiovascular Pharmacology</i> , 2000, 36, S305-S310.                       | 0.8 | 0         |
| 43 | Corresponding distributions of increased endothelin- $\beta$ receptor expression and increased endothelin- $\alpha$ 1 expression in the aorta of apolipoprotein E-deficient mice with advanced atherosclerosis. <i>Pathology International</i> , 2000, 50, 929-936. | 0.6 | 44        |
| 44 | Endothelin-1 and Right-sided Heart Failure in Rats. <i>Journal of Cardiovascular Pharmacology</i> , 2000, 36, S327-S330.  | 0.8 | 1         |
| 45 | Hypotensive Effect of Endothelin-1 via Endothelin-B-Receptor Pathway on Pulmonary Circulation is Enhanced in Rats with Pulmonary Hypertension. <i>Journal of Cardiovascular Pharmacology</i> , 2000, 36, S95-S98.   | 0.8 | 1         |
| 46 | Long-Term Endothelin Receptor Antagonist Administration Improves Alterations in Expression of Various Cardiac Genes in Failing Myocardium of Rats With Heart Failure. <i>Circulation</i> , 2000, 101, 2849-2853.  | 1.6 | 64        |
| 47 | Chronic treatment with probucol effectively inhibits progression of pulmonary hypertension in rats. <i>Life Sciences</i> , 2000, 67, 2017-2023.   | 2.0 | 9         |
| 48 | Expression of endothelin-1, ETA and ETB receptors, and ECE and distribution of endothelin-1 in failing rat heart. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 1999, 276, H1197-H1206.  | 1.5 | 51        |
| 49 | Effects of physiological or pathological pressure load in vivo on myocardial expression of ET-1 and receptors. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 1999, 277, R1321-R1330.                                  | 0.9 | 12        |
| 50 | Role of Endothelin in Deterioration of Heart Failure Due to Cardiomyopathy in Hamsters. <i>Circulation</i> , 1999, 99, 2171-2176.   | 1.6 | 98        |
| 51 | Myocardial expression of endothelin-2 is altered reciprocally to that of endothelin-1 during ischemia of cardiomyocytes in vitro and during heart failure in vivo. <i>Life Sciences</i> , 1999, 65, 1671-1683.  | 2.0 | 14        |
| 52 | Distribution of endothelin-1 in the lung of rats with pulmonary hypertension of different etiology. <i>International Journal of Angiology</i> , 1998, 7, 160-164.   | 0.2 | 5         |
| 53 | Prolonged exercise causes an increase in endothelin-1 production in the heart in rats. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 1998, 275, H2105-H2112.   | 1.5 | 27        |
| 54 | Cloning of Hamster Preproendothelin-1 cDNA and Its Expression in the Heart. <i>Journal of Cardiovascular Pharmacology</i> , 1998, 31, S298-S301.  | 0.8 | 6         |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 55 | Altered Expression of Isoforms of Myosin Heavy Chain mRNA in the Failing Rat Heart Is Ameliorated by Chronic Treatment with an Endothelin Receptor Antagonist. <i>Journal of Cardiovascular Pharmacology</i> , 1998, 31, S302-S305.  | 0.8  | 15        |
| 56 | Endothelin-1 in the Heart During Exercise. <i>Journal of Cardiovascular Pharmacology</i> , 1998, 31, S392-S394.  | 0.8  | 3         |
| 57 | Endothelin-1 Expression in Hearts of Transgenic Hypertensive Mice Overexpressing Angiotensin II. <i>Journal of Cardiovascular Pharmacology</i> , 1998, 31, S412-S416.  | 0.8  | 17        |
| 58 | Endothelin-Converting Enzyme and Angiotensin-Converting Enzyme in Failing Hearts of Rats with Myocardial Infarction. <i>Journal of Cardiovascular Pharmacology</i> , 1998, 31, S417-S420.  | 0.8  | 16        |
| 59 | DOWN-REGULATION OF ET <sub>b</sub> RECEPTOR, BUT NOT ET <sub>a</sub> RECEPTOR, IN CONGESTIVE LUNG SECONDARY TO HEART FAILURE. ARE MARKED INCREASES IN CIRCULATING ENDOTHELIN-1 PARTLY ATTRIBUTABLE TO DECREASES IN LUNG ET <sub>b</sub> RECEPTOR-MEDIATED CLEARANCE OF ENDOTHELIN-1?. <i>Life Sciences</i> , 1997, 62, 185-193.  | 2.0  | 47        |
| 60 | Pulmonary hypertension caused by congestive heart failure is ameliorated by long-term application of an endothelin receptor antagonist Increased expression of endothelin-1 messenger ribonucleic acid and endothelin-1-like immunoreactivity in the lung in congestive heart failure in rats. <i>Journal of the American College of Cardiology</i> , 1996, 28, 1580-1588. | 1.2  | 96        |
| 61 | Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. <i>Nature</i> , 1996, 384, 353-355.  | 13.7 | 623       |
| 62 | Endogenous Endothelin-1 Participates in the Maintenance of Cardiac Function in Rats With Congestive Heart Failure. <i>Circulation</i> , 1996, 93, 1214-1222.   | 1.6  | 244       |
| 63 | The Effect of Bosentan, a New Potent Endothelin Receptor Antagonist, on the Pathogenesis of Cerebral Vasospasm. <i>Neurosurgery</i> , 1995, 37, 87-91.   | 0.6  | 70        |
| 64 | Elevated levels of plasma endothelin-1 in young patients with pulmonary hypertension caused by congenital heart disease are decreased after successful surgical repair. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 1995, 110, 271-273.  | 0.4  | 82        |
| 65 | Increased production of endothelin-1 in the hypertrophied rat heart due to pressure overload. <i>FEBS Letters</i> , 1993, 332, 31-34.  | 1.3  | 104       |